|
|
|
| home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace |
|
|
 WHITE PAPERS |
|
Medpace
|
|
The Promise and Challenge of Adaptive Design in Oncology Trials
|
|
Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.
Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
RWS Life Sciences Welcomes New VP of Quality
RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice
President, Global Quality and Process, in charge of the strategic
direction and implementation of its Quality system, underlying
organizational processes, and change management.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Emerade® Auto-Injector
SHL Group
The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >> |
|
 |
Industry Events |
 |
SMi’s 9th Annual Biosimilars & Biobetters Conference
25-27 September 2018, Copthorne Tara Hotel, London, UK
Following the success of our previous events in both London and the US,
Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker
line-up and bring together a global audience of biosimilar experts to
discuss the latest developments and future of the rapidly evolving and
expanding biosimilars market.
More info >> |
|
|
|
